A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

Brenda Wittman, John Horan, Joanna Baxter, John Goldberg, Raymond Felgar, Erin Baylor, Bean Cromwell, Nicholas Cross, John M. Bennett

Research output: Contribution to journal › Article

18 Citations (Scopus)

Abstract

Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

Original languageEnglish
JournalLeukemia Research
Volume28
Issue numberSUPPL. 1
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Platelet-Derived Growth Factor beta Receptor
Myeloproliferative Disorders
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene Fusion
Cytogenetics
Pediatrics
Imatinib Mesylate
Therapeutics

Keywords

  • Atypical CML
  • ETV6-PDGFRB fusion gene
  • Imatinib mesylate
  • t(5;12)

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Wittman, B., Horan, J., Baxter, J., Goldberg, J., Felgar, R., Baylor, E., ... Bennett, J. M. (2004). A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leukemia Research, 28(SUPPL. 1). https://doi.org/10.1016/j.leukres.2003.10.011

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. / Wittman, Brenda; Horan, John; Baxter, Joanna; Goldberg, John; Felgar, Raymond; Baylor, Erin; Cromwell, Bean; Cross, Nicholas; Bennett, John M.

In: Leukemia Research, Vol. 28, No. SUPPL. 1, 01.05.2004.

Research output: Contribution to journal › Article

Wittman, B, Horan, J, Baxter, J, Goldberg, J, Felgar, R, Baylor, E, Cromwell, B, Cross, N & Bennett, JM 2004, 'A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate', Leukemia Research, vol. 28, no. SUPPL. 1. https://doi.org/10.1016/j.leukres.2003.10.011
Wittman B, Horan J, Baxter J, Goldberg J, Felgar R, Baylor E et al. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leukemia Research. 2004 May 1;28(SUPPL. 1). https://doi.org/10.1016/j.leukres.2003.10.011
Wittman, Brenda ; Horan, John ; Baxter, Joanna ; Goldberg, John ; Felgar, Raymond ; Baylor, Erin ; Cromwell, Bean ; Cross, Nicholas ; Bennett, John M. / A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. In: Leukemia Research. 2004 ; Vol. 28, No. SUPPL. 1.
@article{e23ef9689a464963b67e2561080f8e04,
title = "A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate",
abstract = "Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.",
keywords = "Atypical CML, ETV6-PDGFRB fusion gene, Imatinib mesylate, t(5;12)",
author = "Brenda Wittman and John Horan and Joanna Baxter and John Goldberg and Raymond Felgar and Erin Baylor and Bean Cromwell and Nicholas Cross and Bennett, {John M.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1016/j.leukres.2003.10.011",
language = "English",
volume = "28",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

AU - Wittman, Brenda

AU - Horan, John

AU - Baxter, Joanna

AU - Goldberg, John

AU - Felgar, Raymond

AU - Baylor, Erin

AU - Cromwell, Bean

AU - Cross, Nicholas

AU - Bennett, John M.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

AB - Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/ myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.

KW - Atypical CML

KW - ETV6-PDGFRB fusion gene

KW - Imatinib mesylate

KW - t(5;12)

UR - http://www.scopus.com/inward/record.url?scp=1342279448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342279448&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.10.011

DO - 10.1016/j.leukres.2003.10.011

M3 - Article

VL - 28

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - SUPPL. 1

ER -

Access to Document